Harvey M Friedman Selected Research

Infections

9/2023	Rapid and accurate detection of herpes simplex virus type 2 using a low-cost electrochemical biosensor.
1/2023	A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1.
1/2022	An mRNA vaccine to prevent genital herpes.
12/2021	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models.
12/2021	Guinea Pig and Mouse Models for Genital Herpes Infection.
11/2020	Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.
1/2020	Vaccines to prevent genital herpes.
1/2020	Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.
1/2020	Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.
1/2020	An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harvey M Friedman Research Topics

Disease

31	Infections 09/2023 - 12/2003
21	Herpes Genitalis (Genital Herpes) 10/2023 - 10/2011
6	Genital Diseases 01/2023 - 02/2014
4	Neonatal herpes 11/2020 - 01/2017
4	Reinfection 12/2017 - 04/2011
2	COVID-19 01/2022 - 12/2021
2	Asymptomatic Infections 01/2020 - 01/2019
2	Latent Infection 01/2020 - 08/2015
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/2012 - 11/2011
1	Herpes Zoster 12/2017
1	Pain (Aches) 01/2017
1	Vaginal Diseases 04/2012
1	Herpes Simplex 01/2006
1	Ganglion Cysts (Ganglion) 11/2005

Drug/Important Bio-Agent (IBA)

25	VaccinesIBA 10/2023 - 01/2006
14	Glycoproteins (Glycoprotein)IBA 11/2020 - 10/2004
9	AntigensIBA 09/2023 - 02/2014
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2008
7	AntibodiesIBA 01/2022 - 12/2003
6	Messenger RNA (mRNA)IBA 01/2023 - 01/2019
6	NucleosidesIBA 01/2023 - 01/2019
6	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 04/2012
4	mRNA VaccinesIBA 01/2022 - 01/2020
3	Lipid NanoparticlesIBA 01/2023 - 11/2020
3	Neutralizing AntibodiesIBA 01/2022 - 01/2018
3	Immunoglobulin G (IgG)IBA 04/2011 - 09/2005
2	glycoprotein D-herpes simplex virus type 2IBA 10/2023 - 01/2022
2	EpitopesIBA 01/2022 - 01/2018
2	Subunit VaccinesIBA 01/2020 - 08/2014
2	Monoclonal AntibodiesIBA 01/2018 - 12/2003
2	herpes simplex virus type 1 glycoprotein gCIBA 08/2015 - 02/2014
2	GC 1 compoundIBA 11/2009 - 09/2005
1	Indicators and Reagents (Reagents)IBA 12/2021
1	CytokinesIBA 12/2021
1	aluminum sulfate (alum)IBA 11/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Imiquimod (Aldara)FDA LinkGeneric 01/2019
1	Capsid Proteins (Capsid Protein)IBA 08/2015
1	Acetic Acid (Vinegar)FDA LinkGeneric 03/2012
1	Viral ProteinsIBA 09/2010
1	Retinaldehyde (Retinal)IBA 09/2009
1	Lactose FDA LinkGeneric 01/2009
1	CarbohydratesIBA 01/2009
1	Galectin 3 (LGALS3)IBA 01/2009
1	NectinsIBA 02/2008
1	Keratins (Keratin)IBA 01/2006
1	Viral AntigensIBA 11/2005
1	Blocking AntibodiesIBA 09/2005
1	Small Interfering RNA (siRNA)IBA 10/2004

Therapy/Procedure

1	Euthanasia (Mercy Killing) 12/2021
1	Punctures 12/2021
1	Therapeutics 01/2020
1	Immunotherapy 12/2017